| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.06 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | 0.093 | 0.06 |
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.06 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.06 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.074 | 0.07 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.075 | 0.07 |
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.07 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.07 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.077 | 0.07 |